| Date Filed | Type | Description |
| 10/10/2023 |
15-12G
| Form 15-12G - Securities registration termination [Section 12(g)]: |
| 10/10/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 09/27/2023 |
SC 13D/A
| REGENERON PHARMACEUTICALS, INC. reports a 100% stake in Decibel Therapeutics, Inc. |
| 08/25/2023 |
SC 14D9
| Form SC 14D9 - Solicitation, recommendation statements: |
| 08/25/2023 |
SC TO-T
| Form SC TO-T - Tender offer statement by Third Party: |
| 08/25/2023 |
8-K
| Other Events Interactive Data |
| 08/18/2023 |
SC 13D
| REGENERON PHARMACEUTICALS, INC. reports a 8.3% stake in Decibel Therapeutics, Inc. |
| 08/11/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/09/2023 |
SC14D9C
| Form SC14D9C - Written communication relating to third party tender offer: |
| 08/09/2023 |
SC TO-C
| Form SC TO-C - Written communication relating to an issuer or third party: |
| 08/09/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Agreement and Plan of Merger, by and among Decibel Therapeutics, Inc., Regeneron Pharmaceuticals, Inc., and Symphony Acquisition Sub, Inc",
"Form of Contingent Value Right Agreement, by and among Regeneron Pharmaceuticals, Inc., Symphony Acquisition Sub, Inc. and a rights agent mutually agreeable to Regeneron Pharmaceuticals, Inc. and Decibel Therapeutics, Inc",
"Form of Tender and Support Agreement, by and among Regeneron Pharmaceuticals, Inc., Symphony Acquisition Sub, Inc. and certain Stockholders of Decibel Therapeutics, Inc",
"Regeneron to Acquire Decibel Therapeutics, Strengthening Gene Therapy and Hearing Loss Programs Proposed acquisition builds on existing collaboration between Decibel and Regeneron, will accelerate and further resource key gene therapy programs for hearing loss Decibel's lead investigational gene therapy DB-OTO, designed to provide hearing to people with otoferlin-related hearing loss, is in its first clinical trial" |
|
| 05/15/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/28/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/28/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/14/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 04/06/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits ... |
| 03/21/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/14/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/03/2023 |
SC 13G
| BlackRock Inc. reports a 7.2% stake in DECIBEL THERAPEUTICS INC |
| 01/09/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 11/09/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 10/17/2022 |
8-K
| Other Events Interactive Data |
| 10/12/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 09/20/2022 |
8-K
| Other Events Interactive Data |
| 09/13/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/10/2022 |
8-K
| Quarterly results |
| 08/10/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 08/10/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 06/28/2022 |
8-K
| Quarterly results |
| 06/17/2022 |
8-K
| Quarterly results |
| 05/18/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 05/12/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
|